About CEMIR
About us
The vision of the Centre of Molecular Inflammation Research (CEMIR) is to lay the foundation for identifying new therapeutic targets and developing new diagnostic tools for inflammatory diseases.
This will happen through an integrated 10-year programme of research and research training in molecular innate immune responses. CEMIR was established on 10. June 2013 as a Centre of Excellence (SFF) appointed by the Research Council of Norway.
Objectives
Inflammation is a host response that is triggered by infection and tissue injury. A controlled inflammatory response is needed to fight infections and to heal wounds, but it can become detrimental if it is dysregulated as seen in chronic inflammatory disorders like cardiovascular disease, diabetes, Alzheimer's disease, inflammatory bowel disease, obesity, cancer, and others.
Drawing on major recent advances in the field of innate immunity and cell biology, CEMIR's research programme will detail the molecular and cell biological principles for initiation and regulation of inflammatory responses through the use of basic research, in vitro- and in vivo models and unique biobanks. The localisation of CEMIR in an integrated University hospital environment will facilitate translational research on human disease.
Host institution
Centre of Molecular Inflammation Research is hosted by the Faculty of Medicine and Health Sciences (MH) at the Norwegian University of Science and Technology (NTNU).
CEMIR is one of six research units at the Department of Clinical and Molecular Medicine, NTNU. Our research activities are located in Kunnskapssenteret at Campus Øya and St. Olavs hospital in Trondheim.
Board
- Torstein Baade Rø, Vice-dean, Faculty of Medicine and Health Sciences, NTNU
- Magnus Steigedal, Head of Department, Department of Clinical and Molecular Medicine, NTNU
- Lars Gunnar Landrø, Head of Department, Department of Biomedical Laboratory Science, NTNU
- Gilda Susan Opland, Head of Clinic, Laboratoriemedisinsk klinikk, St. Olavs hospital
Scientific Advisory Board
- Alan Aderem, Seattle Children's Hospital, USA
- Douglas Golenbock, University of Massachusetts Medical School, USA
- Göran Hansson, Karolinska Institutet (KI), Sverige
- Lynda Stuart, University of Washington, USA
- Stefanie Vogel, University of Maryland Medical Center (UMMC), USA
Cooperation
CEMIR works in close cooperation with St. Olavs hospital and Central Norway Regional Health Authority, Helse Midt-Norge
